Year in review 2013: Chronic obstructive pulmonary disease, asthma and airway biology

Ko, Fanny W.S.; Lim, Tow Keang; Hancox, Robert J.; Yang, Ian A.

doi:10.1111/resp.12252

Cited by 2 publications

(3 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asthma and COPD affect more than one-half billion people globally resulting in billions of dollars in healthcare costs, and there are no cures 1 2 3 4 5 . These diseases are characterized by excessive inflammation that is often exacerbated by bacterial respiratory infections, such as NTHi 6 7 .…”

Section: Discussionmentioning

confidence: 99%

“…These diseases are characterized by excessive inflammation that is often exacerbated by bacterial respiratory infections, such as NTHi 6 7 . The increasing numbers of antibiotic-resistant NTHi strains, tolerance issues and adverse side effects of currently available therapies, together with the increasing prevalence of airway diseases requires the development of novel, non-antibiotic therapeutics 5 10 11 . Resveratrol is being widely studied for its therapeutic potential for a vast array of diseases 28 29 30 .…”

Section: Discussionmentioning

confidence: 99%

“…The World Health Organization predicts that by the year 2020, COPD will be the fifth most significant contributor to the worldwide burden of disease 4 . Billions of dollars in healthcare costs are associated with these diseases and there are no cures 1 5 . These airway diseases are characterized by chronic inflammation resulting in epithelial injury and airflow limitation and exacerbations are often caused by respiratory pathogens such as nontypeable Haemophilus influenzae (NTHi) 6 7 .…”

mentioning

confidence: 99%

See 2 more Smart Citations

Resveratrol suppresses NTHi-induced inflammation via up-regulation of the negative regulator MyD88 short

Andrews

Matsuyama

Lee

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Upper respiratory tract inflammatory diseases such as asthma and chronic obstructive pulmonary diseases (COPD) affect more than one-half billion people globally and are characterized by chronic inflammation that is often exacerbated by respiratory pathogens such as nontypeable Haemophilus influenzae (NTHi). The increasing numbers of antibiotic-resistant bacterial strains and the limited success of currently available pharmaceuticals used to manage the symptoms of these diseases present an urgent need for the development of novel anti-inflammatory therapeutic agents. Resveratrol has long been thought as an interesting therapeutic agent for various diseases including inflammatory diseases. However, the molecular mechanisms underlying its anti-inflammatory properties remain largely unknown. Here we show for the first time that resveratrol decreases expression of pro-inflammatory mediators in airway epithelial cells and in the lung of mice by enhancing NTHi-induced MyD88 short, a negative regulator of inflammation, via inhibition of ERK1/2 activation. Furthermore, resveratrol inhibits NTHi-induced ERK1/2 phosphorylation by increasing MKP-1 expression via a cAMP-PKA-dependent signaling pathway. Finally, we show that resveratrol has anti-inflammatory effects post NTHi infection, thereby demonstrating its therapeutic potential. Together these data reveal a novel mechanism by which resveratrol alleviates NTHi-induced inflammation in airway disease by up-regulating the negative regulator of inflammation MyD88s.

show abstract